Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference
Neos Therapeutics, a pharmaceutical company focused on central nervous system products, announced that CEO Jerry McLaughlin will take part in a pre-recorded presentation at the H.C. Wainwright Virtual BioConnect Conference. This presentation will be accessible on the company's Investor Relations page starting January 11, 2021, at 6:00 a.m. ET, with a replay available for 30 days. Neos markets various ADHD treatments, including Adzenys XR-ODT and Cotempla XR-ODT, and is developing NT0502 for sialorrhea in neurological patients.
- None.
- None.
DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference.
The presentation will be available for on-demand viewing on the Investor Relations page of the company’s website at http://investors.neostx.com/ beginning Monday, January 11, 2021 at 6:00 a.m. ET. A replay of the webcast will be available on Neos’ website for 30 days.
About Neos Therapeutics
Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products. Neos markets Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD. Neos also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions. Additional information about Neos is available at www.neostx.com.
CONTACTS:
Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah.mccabe@sternir.com
FAQ
What is the date of Neos Therapeutics' presentation at the H.C. Wainwright Virtual BioConnect Conference?
How can I access the Neos Therapeutics presentation online?
What products does Neos Therapeutics market for ADHD treatment?
What is NT0502 developed by Neos Therapeutics?
